FindTrial
Sign In

AN0025

DRUG4 trials

Sponsors

Adlai Nortye Biopharma Co., Ltd., Rutgers, The State University of New Jersey

Conditions

Cervical CancerEsophageal CancerLocally Advanced Solid TumorLung Cancer Stage IIIMicrosatellite Stable (MSS) Colorectal Cancer (CRC)NSCLC, Squamous or Non-SquamousTriple-negative Breast CancerUrothelial Carcinoma of the Bladder

Phase 1

AN0025 and Pembrolizumab Combination in Advanced Solid Tumors
Active, not recruitingNCT04432857
Adlai Nortye Biopharma Co., Ltd.Cervical Cancer, Microsatellite Stable (MSS) Colorectal Cancer (CRC), NSCLC, Squamous or Non-Squamous +2
Start: 2020-08-20End: 2025-01-30Updated: 2024-06-27
Double/Triple Combinations of AN2025, AN0025 and Atezolizumab in Advanced Solid Tumors
CompletedNCT04975958
Adlai Nortye Biopharma Co., Ltd.Locally Advanced Solid Tumor
Start: 2021-09-07End: 2025-01-24Updated: 2025-06-22
AN0025 and Chemoradiotherapy Combination in Esophageal Cancer
SuspendedNCT05191667
Adlai Nortye Biopharma Co., Ltd.Esophageal Cancer
Start: 2022-01-18End: 2025-12-31Target: 32Updated: 2025-02-13
A Trial of AN0025 With Chemoradiation Therapy in Stage III NSCLC Participants
WithdrawnNCT05358691
Rutgers, The State University of New JerseyLung Cancer Stage III
Start: 2024-11-01End: 2028-06-01Updated: 2025-04-16

Related Papers

AN0025 in combination with definitive chemoradiotherapy (dCRT) in unresectable locally advanced or locally recurrent esophageal cancer (EC): A single-arm, open-label, multicenter, phase Ib study.
Journal of Clinical Oncology2024-06-01